Organon & Co., a global healthcare company specializing in women's health, has announced results from their Phase 2 ELENA proof-of-concept study. The study evaluated the investigational candidate OG-6219, an oral 17β-hydroxysteroid dehydrogenase type 1 inhibitor, in patients with endometriosis-related pain. The trial did not meet its primary efficacy endpoint, as OG-6219 failed to demonstrate improvement in moderate-to-severe endometriosis-related overall pelvic pain compared to placebo. Consequently, Organon plans to discontinue the clinical development program for OG-6219. The study was a randomized, double-blind, placebo-controlled, global multi-center trial involving pre-menopausal women aged 18 to 49 with surgically diagnosed endometriosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.